BONTAC NMN in Research Co-Authored by Harvard’s David Sinclair

Harvard Medical School Researcher · David A. Sinclair
Published in Cell · 2018

NMN Used in Research Co-Authored by Harvard’s David Sinclair.

BONTAC supplied the NMN used by the research team in a 2018 preclinical study published in Cell and co-authored by Harvard Medical School researcher David A. Sinclair. The study’s reported NMN-treatment findings were therefore generated using BONTAC-supplied NMN.

View Page 89 of the Study Shop Novera NMN
Documented in the methods

The Source Is Named Directly.

The article’s Key Resources Table identifies the material used by the research team. The relevant entry appears on page 89 of the published PDF:

Reagent or resource Source Identifier
Nicotinamide mononucleotide Bontac Bio-Engineering, China N/A

This supplier entry establishes that the NMN administered in the study’s NMN-treatment experiments came from BONTAC. Accordingly, the NMN-treatment observations reported by the authors were obtained using BONTAC-supplied material.

Key Resources Table · Page 89. This is a faithful text reproduction of the supplier entry; consult the complete publication for full methods and context.

Open the Published PDF
What the evidence shows

Strong Evidence, Precisely Stated.

Published research The work appeared in the peer-reviewed scientific journal Cell in 2018.
Harvard co-author David A. Sinclair of Harvard Medical School is among the study’s authors.
Named NMN supplier The Key Resources Table lists Bontac Bio-Engineering as the source of the NMN used in the study’s treatment experiments.
Preclinical context The research was preclinical; it was not a clinical trial of the finished Novera product.

Das A, Huang GX, Bonkowski MS, et al. Impairment of an Endothelial NAD+-H₂S Signaling Network Is a Reversible Cause of Vascular Aging. Cell. 2018;173(1):74–89.e20. doi:10.1016/j.cell.2018.02.008.

The BONTAC story

A Pioneer in Enzymatic NMN Manufacturing.

Founded in 2012, BONTAC specializes in the biosynthesis of coenzymes. The company describes itself as an early pioneer of large-scale NMN production and uses advanced fully enzymatic manufacturing together with its Bonpure® seven-step purification technology.

Advanced enzymatic process Developed for efficient, high-purity coenzyme production.
Bonpure® purification A proprietary seven-step purification approach.
NMN-focused innovation A portfolio of patent applications related to NMN and coenzyme production.
Documented raw material Identity and purity are evaluated through product and batch documentation.
Explore NMN & NAD+ Science NMN vs. NR vs. NAD+
From source to finished product

BONTAC Innovation. Japanese Manufacturing. Novera Verification.

Novera begins with BONTAC® β-NMN and completes finished-product manufacturing in Japan under certified GMP standards. Each bottle provides 500 mg per capsule, and quality documentation is available for verification.

The NMN used in research co-authored by Harvard Medical School’s David A. Sinclair—and published in Cell—was supplied by BONTAC. Why settle for an unnamed NMN source?

BONTAC® β-NMN Finished in Japan 99.9% Batch Purity Documents Available
Shop Novera NMN Verify Quality NMN Buying Guide

Research clarification: The cited study evaluated BONTAC-supplied NMN, not the finished Novera product. The study was preclinical. No endorsement of Novera by the study’s authors, Harvard Medical School or Cell is stated or implied. This content is educational and is not intended to diagnose, treat, cure or prevent any disease.